Aptose Biosciences Inc.
APTODelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000882361
Aptose Biosciences Inc. was delisted in 2025; its insiders filed their last Form 4 on Jul 2, 2026; 24 institutions reported holding it in 13F filings for Q4 2024, worth $892.9K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 24
- Q4 2024, −1 vs. previous quarter
- 13F value
- $892.9K
- Reported value at the end of Q4 2024
- Superinvestors holding
- 0
- At the end of Q4 2024
Superinvestors holding APTO, Q4 2024
No superinvestor reported holding APTO at the end of Q4 2024.
Latest insider trades
Open-market purchases and sales by Aptose Biosciences Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 26, 2024 (view filing)6:56 PM ET | Nov 25 | 1 day | Rice William G.Chair, President & CEO | PPurchase | +100.0K | $0.20 | +$20.0K | +19.5%613.3K after | |
| Nov 26, 2024 (view filing)6:56 PM ET | Nov 25 | 1 day | Rice William G.Chair, President & CEO | PPurchase | +50.0K | – | – | –50.0K after | Derivative |
| Sep 25, 2023 (view filing) | Sep 22 | 3 days | Seizinger Bernd R.Director | PPurchase | +17.0K | $3.14 | +$53.4K | New position17.0K after | |
| Sep 21, 2022 (view filing) | Sep 19 | 2 days | Rice William G.Chair, President & CEO | PPurchase | +10.0K | $0.68 | +$6.80K | +2.8%363.3K after | |
| Sep 21, 2022 (view filing) | Sep 19 | 2 days | Payne FletcherSR VP & Chief Fin. Officer | PPurchase | +10.0K | $0.68 | +$6.80K | New position10.0K after | |
| Jun 6, 2022 (view filing) | Jun 6 | Same day | Rice William G.Chair, President & CEO | PPurchase | +10.0K | $0.97 | +$9.70K | +2.9%353.3K after | |
| Dec 20, 2021 (view filing) | Dec 16 | 4 days | Platzer ErichDirector | PPurchase | +100.0K | $1.38 | +$137.9K | +24.7%505.0K after | 3 lots |
| Dec 17, 2021 (view filing) | Dec 15 | 2 days | Platzer ErichDirector | PPurchase | +270.0K | $1.17 | +$316.9K | +200.0%405.0K after | 4 lots |
| Dec 17, 2021 (view filing) | Dec 16 | 1 day | Rice William G.Chair, President & CEO | PPurchase | +13.2K | $1.52 | +$20.0K | +4.0%343.3K after | |
| Dec 15, 2021 (view filing) | Dec 15 | Same day | Rice William G.Chair, President & CEO | PPurchase | +17.8K | $1.12 | +$20.0K | +5.7%330.1K after |
Top 10 13F holders, Q4 2024
The largest institutional positions in Aptose Biosciences Inc. at the end of Q4 2024; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bleichroeder LP | 2,500,000 | $563.3K | 0.14% | +2,500,000 | New |
| Sigma Planning Corp | 703,384 | $158.5K | 0.00% | +301,634+75.1% | Added |
| DRW Securities, LLC | 592,829 | $133.6K | 0.01% | 00.0% | Unchanged |
| UBS Group AG | 57,827 | $13.0K | 0.00% | −75,649−56.7% | Reduced |
| HRT Financial LP | 43,112 | $9.00K | 0.00% | +43,112 | New |
| Annandale Capital, LLC | 26,666 | $6.00K | 0.00% | 00.0% | Unchanged |
| Cetera Investment Advisers | 19,206 | $4.40K | 0.00% | −80.0% | Reduced |
| Two Sigma Securities, LLC | 11,398 | $2.57K | 0.00% | −19,029−62.5% | Reduced |
| Morgan Stanley | 5,501 | $1.24K | 0.00% | −25,852−82.5% | Reduced |
| US Bancorp | 2,020 | $455 | 0.00% | 00.0% | Unchanged |